BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31406093)

  • 1. An Improved Protocol for the Virtual Screening Discovery of Novel Histone Deacetylase Inhibitors.
    Song Q; Liu T; Liu Y; Wang S; Fan C; Zheng L; Bao Y; Sun L; Yu C; Sun Y; Song Z; Wang G; Huang Y; Li Y
    Chem Pharm Bull (Tokyo); 2019 Oct; 67(10):1076-1081. PubMed ID: 31406093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.
    Fan W; Zhang L; Wang X; Jia H; Zhang L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):707-718. PubMed ID: 33663315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
    Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screening and experimental validation of novel histone deacetylase inhibitors.
    Huang YX; Zhao J; Song QH; Zheng LH; Fan C; Liu TT; Bao YL; Sun LG; Zhang LB; Li YX
    BMC Pharmacol Toxicol; 2016 Jul; 17(1):32. PubMed ID: 27443303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors.
    Gediya P; Vyas VK; Carafa V; Sitwala N; Della Torre L; Poziello A; Kurohara T; Suzuki T; Sanna V; Raguraman V; Suthindhiran K; Ghosh D; Bhatia D; Altucci L; Ghate MD
    Bioorg Chem; 2021 May; 110():104801. PubMed ID: 33756235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a series of small molecules as potent histone deacetylase inhibitors.
    Zhang L; Wang X; Li X; Xu W
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):333-7. PubMed ID: 23534931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
    Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
    Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors.
    Gong G; Qi J; Lv Y; Dong S; Cao C; Li D; Zhao R; Li Z; Chen X
    Chem Pharm Bull (Tokyo); 2020; 68(5):466-472. PubMed ID: 32378544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
    El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
    Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.
    Xie R; Li Y; Tang P; Yuan Q
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4415-4420. PubMed ID: 28818449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
    Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
    Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
    Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
    Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
    Kumar N; Tomar R; Pandey A; Tomar V; Singh VK; Chandra R
    Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1288-1299. PubMed ID: 28847179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
    Muthyala R; Shin WS; Xie J; Sham YY
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4320-4. PubMed ID: 26264503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.